{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:44:56Z","timestamp":1782459896400,"version":"3.54.5"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Andexanet alfa is a recombinant modified factor Xa decoy protein used to reverse the anticoagulant effects of direct oral factor Xa inhibitors, including apixaban, rivaroxaban, and edoxaban. While effective in controlling life-threatening bleeding, it may induce heparin resistance, which complicates anticoagulation during procedures requiring urgent revascularization. Its potential to cause significant heparin resistance during percutaneous coronary intervention (PCI) has been reported only rarely and remains underrecognized. This phenomenon poses a major therapeutic dilemma when emergent PCI is required, especially in life-threatening settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>An 82-year-old man on edoxaban for atrial tachycardia presented with a left iliac bone fracture and expanding haematoma. Andexanet alfa was administered to reverse anticoagulation. Shortly thereafter, he developed acute anterior ST-segment elevation myocardial infarction (STEMI). Emergency PCI revealed a new occlusion in the proximal left anterior descending artery. Despite receiving 30 000 units of unfractionated heparin, the activated clotting time reached only 249\u2005s after a 36-min delay, consistent with heparin resistance. Intra-aortic balloon pumping and veno-arterial extracorporeal membrane oxygenation were required to stabilize haemodynamics. Although revascularization was successfully completed, the patient ultimately died from pneumonia on post-operative Day 21.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Although STEMI following andexanet alfa administration has been reported, this case underscores the additional challenge of profound heparin resistance compromising timely anticoagulation during emergent PCI. Rapid recognition of andexanet alfa\u2013induced heparin resistance is crucial in urgent PCI settings to ensure effective anticoagulation and prevent procedural delays that may compromise outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaf497","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:05:37Z","timestamp":1759320337000},"source":"Crossref","is-referenced-by-count":2,"title":["Andexanet alfa\u2013induced heparin resistance during percutaneous coronary intervention for ST-elevation myocardial infarction: a case report"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7899-8099","authenticated-orcid":false,"given":"Satoru","family":"Sasaki","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Yodogawa Christian Hospital , 1-7-50 Kunijima, Higashiyodogawa-ku, Osaka, Osaka 533-0024 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Yodogawa Christian Hospital , 1-7-50 Kunijima, Higashiyodogawa-ku, Osaka, Osaka 533-0024 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takeshige","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Yodogawa Christian Hospital , 1-7-50 Kunijima, Higashiyodogawa-ku, Osaka, Osaka 533-0024 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Iwata","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Yodogawa Christian Hospital , 1-7-50 Kunijima, Higashiyodogawa-ku, Osaka, Osaka 533-0024 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"2025102312160432900_ytaf497-B1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCRESAHA.113.302297","article-title":"The real decoy: an antidote for factor Xa-directed anticoagulants","volume":"113","author":"Yeh","year":"2013","journal-title":"Circ Res"},{"key":"2025102312160432900_ytaf497-B2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"2025102312160432900_ytaf497-B3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/phar.2306","article-title":"Intraoperative unfractionated heparin unresponsiveness during endovascular repair of a ruptured abdominal aortic aneurysm following administration of andexanet alfa for the reversal of rivaroxaban","volume":"39","author":"Eche","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2025102312160432900_ytaf497-B4","first-page":"390","article-title":"Difficult intraoperative heparinization following andexanet alfa administration","volume":"3","author":"Watson","year":"2019","journal-title":"Clin Pract Cases Emerg Med"},{"key":"2025102312160432900_ytaf497-B5","doi-asserted-by":"crossref","first-page":"ytaf136","DOI":"10.1093\/ehjcr\/ytaf136","article-title":"Andexanet alfa for reversal of intracerebral haemorrhage resulting in ST-segment myocardial infarction: a case report","volume":"9","author":"Mehrara","year":"2025","journal-title":"Eur Heart J Case Rep"},{"key":"2025102312160432900_ytaf497-B6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.jvca.2020.10.042","article-title":"Successful antithrombin administration in andexanet alfa-associated heparin resistance","volume":"35","author":"Apostel","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2025102312160432900_ytaf497-B7","doi-asserted-by":"crossref","first-page":"e01636","DOI":"10.1213\/XAA.0000000000001636","article-title":"Heparin insensitivity and thrombotic risk associated with sequential uses of prothrombin complex concentrate and andexanet alfa for apixaban reversal during acute type A aortic dissection repair: a case report","volume":"16","author":"Brenner","year":"2022","journal-title":"A A Pract"},{"key":"2025102312160432900_ytaf497-B8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40981-023-00619-7","article-title":"Successful use of an antithrombin for heparin resistance with andexanet alfa","volume":"9","author":"Honda","year":"2023","journal-title":"JA Clin Rep"},{"key":"2025102312160432900_ytaf497-B9","doi-asserted-by":"crossref","first-page":"ezad100","DOI":"10.1093\/ejcts\/ezad100","article-title":"Andexanet alfa in acute aortic syndrome: first UK experience","volume":"63","author":"Al-Attar","year":"2023","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025102312160432900_ytaf497-B10","first-page":"e44003","article-title":"Successful nafamostat mesilate administration for andexanet alfa-induced heparin resistance","volume":"15","author":"Kitaura","year":"2023","journal-title":"Cureus"},{"key":"2025102312160432900_ytaf497-B11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40981-024-00690-8","article-title":"Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report","volume":"10","author":"Suzuki","year":"2024","journal-title":"JA Clin Rep"},{"key":"2025102312160432900_ytaf497-B12","doi-asserted-by":"publisher","author":"Chabata","DOI":"10.1101\/2024.09.09.612152"},{"key":"2025102312160432900_ytaf497-B13","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1053\/j.jvca.2024.05.022","article-title":"Heparin resistance after andexanet alfa\u2014calling on argatroban and nafamostat for rescue?","volume":"38","author":"Mishima","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2025102312160432900_ytaf497-B14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1053\/j.jvca.2024.03.037","article-title":"Andexanet alfa-induced heparin resistance: sustained anticoagulant inefficacy despite antithrombin therapy","volume":"38","author":"Nagashima","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2025102312160432900_ytaf497-B15","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytaf497\/64481509\/ytaf497.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/10\/ytaf497\/64481509\/ytaf497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/10\/ytaf497\/64481509\/ytaf497.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:16:14Z","timestamp":1761236174000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytaf497\/8271907"}},"subtitle":[],"editor":[{"given":"Josip Andelo","family":"Borovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Reshma","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Mislav","family":"Lozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaf497","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10,1]]},"article-number":"ytaf497"}}